Compare CACC & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | MMED |
|---|---|---|
| Founded | 1972 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.7B |
| IPO Year | 1996 | 2025 |
| Metric | CACC | MMED |
|---|---|---|
| Price | $590.41 | $22.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $505.00 | $22.56 |
| AVG Volume (30 Days) | 83.6K | ★ 1.9M |
| Earning Date | 05-05-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.00 | N/A |
| EPS | ★ 25.04 | N/A |
| Revenue | $2,317,200,000.00 | ★ $3,102,000,000.00 |
| Revenue This Year | $91.73 | $15.99 |
| Revenue Next Year | $3.58 | $10.00 |
| P/E Ratio | $24.02 | ★ N/A |
| Revenue Growth | 7.16 | ★ 14.25 |
| 52 Week Low | $401.90 | $10.65 |
| 52 Week High | $668.86 | $24.43 |
| Indicator | CACC | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 62.94 |
| Support Level | $589.36 | $10.68 |
| Resistance Level | $621.24 | $24.43 |
| Average True Range (ATR) | 12.93 | 1.08 |
| MACD | 0.23 | -0.12 |
| Stochastic Oscillator | 51.15 | 63.70 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.